专科重度哮喘管理的获益:人口学与地理差异
该研究在英国重度哮喘生物制剂时代,对12家专科中心1140例患者进行非对照前后对比,随访1年。结果显示专科评估与管理可显著改善哮喘控制、减少急性发作和急诊使用、改善肺功能并减少口服激素用量,获益在各人口学组中基本一致,但不同医院间结局差异超过2倍。
要点
- 专科管理1年后ACQ-6中位降低0.7,急性发作减少75%,非计划二级医疗使用减少100%。
- FEV1中位增加20 mL,67%患者口服激素剂量下降。
- ≥65岁患者急性发作和非计划医疗减少幅度大于18-34岁患者。
核心结论
- 专科评估与管理与重度哮喘患者结局显著改善相关,且获益不限于接受生物制剂治疗者。
- 获益在人口学组间基本一致,但医院间存在显著差异。
研究设计与样本
- 非对照前后对比研究,纳入12家专科中心1140例患者,随访1370人年,比较1年后结局。
主要发现
- ACQ-6评分中位(IQR)降低0.7(0.0-1.5)。
- 急性发作减少75%(33-100%),非计划二级医疗使用减少100%(67-100%)。
- FEV1中位(IQR)增加20(-200-340)mL,67%患者口服激素剂量下降。
- ≥65岁患者急性发作减少69% vs 18-34岁52%(p<0.001),非计划医疗使用减少77% vs 50%(p<0.001)。
- 最佳与最差中心间所有研究结局差异超过2倍。
临床怎么用
- 应将重度哮喘患者转诊至专科评估与管理以改善结局。
- 不应仅限接受生物制剂治疗者,未用生物制剂者亦可从专科管理获益。
- 需关注并调查不同医院间重度哮喘管理结局的显著差异。
局限性
- 非对照前后对比设计,无法排除时间趋势等混杂因素。
- 研究仅纳入12家专科中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefits of specialist assessment and management have yet to be evaluated within the biologic era of UK severe asthma treatment, and potential disparities have not been considered. METHODS: In an uncontrolled before-and-after study, we compared asthma symptoms (Asthma Control Questionnaire-6 (ACQ-6)), exacerbations, unscheduled secondary care use, lung function (forced expiratory volume in 1 s (FEV1)) and oral corticosteroid (OCS) dose after 1 year. We compared outcomes by sex, age (18-34, 35-49, 50-64 and ≥65 years), ethnicity (Caucasian versus non-Caucasian) and hospital site after adjusting for demographics and variation in biologic therapy use. RESULTS: 1140 patients were followed-up for 1370 person-years from 12 specialist centres. At annual review, ACQ-6 score was reduced by a median (interquartile range (IQR)) of 0.7 (0.0-1.5), exacerbations by 75% (33-100%) and unscheduled secondary care by 100% (67-100%). FEV1 increased by a median (IQR) of 20 (-200-340) mL, while OCS dose decreased for 67% of patients. Clinically meaningful improvements occurred across almost all patients, including those not receiving biologic therapy. There was little evidence of differences across demographic groups, although those aged ≥65 years demonstrated larger reductions in exacerbations (69% versus 52%; p<0.001) and unscheduled care use (77% versus 50%; p<0.001) compared with patients aged 18-34 years. There were >2-fold differences between the best and worst performing centres across all study outcomes. CONCLUSIONS: Specialist assessment and management is associated with substantially improved patient outcomes, which are broadly consistent across demographic groups and are not restricted to those receiving biologic therapy. Significant variation exists between hospitals, which requires further investigation.
引用
- Redmond C, Heaney LG, Chaudhuri R, et al. Benefits of specialist severe asthma management: demographic and geographic disparities. Eur Respir J. 2022. PMID: 35777771. doi:10.1183/13993003.00660-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。